Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4601–4650 of 35148
Mr. Wayne Edmunds informed MSCI Inc. (“MSCI” or the “Company”) of his decision to retire from the Board of Directors (the “Board”) of the Company and not stand for re-election at the Company’s 2025 Annual Meeting of Shareholders.
On February 25, 2025, the company’s Board of Directors resolved to acknowledge that Mr. Marino Papazoglou has resigned from the board as a director of the company, effective immediately.
On February 18, 2025, the Board of Pineapple Financial Inc. (the " Company ") received by email a resignation letter from Nima Besharat, a director of the Company, pursuant to which Mr. Besharat resigned as director of the Company, effective immediately.
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
Mr. Semerjian also resigned from the Board of Directors effective as of February 21, 2025.
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
On February 21, 2025, Amy Butte, a member of the Board of Directors (the “Board”) of the Company, notified the Company of her intention not to stand for reelection at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
On February 21, 2025, the board of directors (the “Board”) of Chewy, Inc. (the “Company”) increased the size of the Board from twelve to thirteen directors and filled the newly created vacancy by appointing Ms. Deborah Ellinger (the “New Director”) as a Class II director
the resignation of Patrick McCarter, which was received February 19, 2025 and will become effective at the end of the day on February 28, 2025.
the Company announced the appointment of Rob Giglio to its Board of Directors (“Board”), effective as of March 1, 2025.
the Board approved increasing the size of the Board to 11 members and electing Mr. Rivera to serve as a director, both effective as of the Transition Date.
director C. Todd Asbury will not stand for reelection and will step down from the board of directors effective with the Annual Meeting of Shareholders scheduled for May 20, 2025.
On February 21, 2025, Mag Magna Corp (the "Registrant") approved the appointment of Tomasz Anczok, as Independent Director of the Registrant, to be effective as of February 21, 2025
On February 20, 2025, the Board of Directors (the “Board”) of Independent Bank Corp. (the “Company”) appointed Leif O’Leary, Dawn Perry, and Aparna Ramesh (collectively, the “New Directors”) as members of the Board of Directors of the Company (the “Board”), effective April 1, 2025.
On February 20, 2025, the Board of Directors (the “Board”) of Independent Bank Corp. (the “Company”) appointed Leif O’Leary, Dawn Perry, and Aparna Ramesh (collectively, the “New Directors”) as members of the Board of Directors of the Company (the “Board”), effective April 1, 2025.
On February 20, 2025, the Board of Directors (the “Board”) of Independent Bank Corp. (the “Company”) appointed Leif O’Leary, Dawn Perry, and Aparna Ramesh (collectively, the “New Directors”) as members of the Board of Directors of the Company (the “Board”), effective April 1, 2025.
On February 19, 2025, Mary C. Hemmingsen, a member of the Board and a member of the Audit/Finance Committee, advised the Company that owing to her significant work and board load as partner at Moneta Securities and her audit chair role for four companies, she will not stand for re-election to the Board at the Company's 2025 Annual Meeting of Shareholders.
On February 19, 2025, Lynda L. Ziegler, a member of the Board of Directors (the Board) of Itron, Inc. (the Company), the chair of the Nominating and Corporate Governance Committee, and a member of the Compensation Committee, notified the Company that she will retire when her term ends and, therefore, not stand for re-election to the Board at the Company’s 2025 Annual Meeting of Shareholders.
On February 19, 2025, Robert A. Rango, a member of the Board of Directors (the "Board") of Microchip Technology Incorporated (the "Company"), retired from the Board effective as of February 19, 2025.
On February 19, 2025, Dan O. Dinges informed the Board of Directors (the “Board”) of Coterra Energy Inc. (the “Company”) of his decision to retire from the Board at the end of his current term and not stand for re-election as a director at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
Also on February 19, 2025, Robert S. Boswell informed the Board of his decision to retire from the Board at the end of his current term and not stand for re-election as a director at the 2025 Annual Meeting.
the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz’ resignation.
On February 19, 2025, the Board of Directors of the Company (the “Board”), approved an increase in the size of the Board from nine to ten members and appointed Barak Eilam as a director to fill the vacancy created by the increase.
On February 20, 2025, pursuant to the amended and restated bylaws of Evoke Pharma, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Greg Pyszcymuka to serve as a Class I director, effective immediately, with an initial term expiring at the Company’s 2026 annual meeting of stockholders.
increased the size of the Board from seven to eight directors and appointed Thomas Mullins to serve as an independent member of the Board to fill the resulting vacancy, effective February 18, 2025
the board of directors of the Company (the “Board”) increased the size of the Board from nine directors to ten directors and appointed Lloyd W. “Billy” Helms, Jr. to the resulting vacancy, effective immediately.
On February 19, 2025, Mr. Laurance Narbut notified the Board of Directors (the “Board”) of Barnwell Industries, Inc. (the “Company”) that he resigned as a director of the Company, effective February 19, 2025.
On February 19, 2025, Derek DiRocco, M.D., notified Werewolf Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company, effective upon the Company’s 2025 annual meeting of stockholders.
On February 19, 2025, the Board of the Company, upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Anil Singhal, Ph.D., as a director.
The Board also expanded its size from seven to eight directors and appointed Vincent Aurentz to serve as a Class I director of the Board.
On February 20, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) elected Arthur Kirsch as a Class I director of the Company, effective immediately.
On February 20, 2025, the Board of Directors (the “Board”) of Carpenter Technology Corporation (the “Company”) appointed Julie A. Beck as a member of the Board effective immediately.
Retirement of Meg G. Crofton from the
Richard B. Cassidy II Director
Ellyn J. Shook Director
Necip Sayiner Director
Devinder Kumar Director
the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) increased the size of the Board from eleven to twelve members and appointed Timothy P. Walbert to the Board, to be effective February 24, 2025.
On February 19, 2025, Kellye I. Walker notified the Board of Directors (the “Board”) of Lincoln Electric Holdings, Inc. (the “Company”) of her intention to resign from the Board and not to stand for re-election upon the expiration of her current term, which expires at the Company’s 2025 annual meeting of shareholders.
On February 19, 2025, the Board of the Company increased its size from eleven to twelve members and elected N. Joy Falotico to fill the resulting vacancy.
Ms. Siyun Yang was appointed as an independent director to fill the resulting vacancy, effective immediately.
On February 20, 2025, the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel J. O’Connor to the Board, effective immediately.
On February 18, 2025, the Board of Directors of Skyline Bankshares, Inc. (the “Company”) appointed Israel O’Quinn as a director of the Company and its wholly-owned subsidiary, Skyline National Bank, effective immediately.
On February 21, 2025, the Company’s Board appointed Lavina Talukdar to the Board.
Michael J. Brown has resigned from his position as a member of the Monopar Therapeutics Inc. (the” Company”) Board of Directors (the “Board”) effective February 19, 2025.
Melquiades R. Martinez and Raymond L. Gellein, Jr. notified the Company of their decision to retire from their positions as members of the Board effective immediately prior to the Company’s 2025 annual meeting of stockholders
Melquiades R. Martinez and Raymond L. Gellein, Jr. notified the Company of their decision to retire from their positions as members of the Board effective immediately prior to the Company’s 2025 annual meeting of stockholders
voted to appoint Matthew E. Avril and James A. (“Jim”) Dausch as directors of the Board, effective March 4, 2025.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.